Please assess the completion status of the following clinical trial:

Trial Title: Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must provide informed consent~* Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on the face or scalp~* Subject at least 18 years of age~* Female subjects must be of either:~  * Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or,~ * Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to study treatment, to rule out pregnancy~* Female subjects of childbearing potential must be willing to consent to using highly effective methods of contraception~Exclusion Criteria:~* Location of the selected treatment area:~  * on any location other than the face or scalp~ * on the periorbital skin~ * within 5 cm of an incompletely healed wound~ * within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)~* Prior treatment with ingenol mebutate gel on face or scalp (previous treatment on trunk and extremities acceptable)~* Selected treatment area lesions that have atypical clinical appearance~* History or evidence of skin conditions other than the trial indication that would interfere with evaluation of the trial medication in the selected treatment area~* Anticipated need for hospitalization or out-patient surgery prior to Day 15 in the first treatment cycle~* Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel~* Presence of sunburn within the selected treatment area~* Current enrollment or participation in a clinical trial within 30 days of entry into this study~* Subjects previously entered first treatment in the trial~* Female subjects who are breastfeeding~* Subjects who are institutionalised by court order or by the local authority~* In the opinion of the investigator, the subject is unlikely to comply with the Clinical Study Protocol~Prohibited Therapies and/or Medications within 2 weeks prior to Day 1~* Cosmetic or therapeutic procedures within 2 cm of the selected treatment area~* Use of keratolytic topical therapeutic products within 2 cm of the selected treatment area~* Use of topical medicated creams, ointments, lotions gels, foams or sprays within 2 cm of the selected treatment area; artificial tanners: within 5 cm of the selected treatment area~Prohibited Therapies and/or Medications: within 4 weeks prior to Day 1~* Treatment with immunomodulators, cytotoxic drugs or interferon /interferon inducers~* Treatment with systemic medications that suppress the immune system~* Treatment/therapy with ultraviolet light A (UVA) or ultraviolet light B (UVB)~Prohibited Therapies and/or Medications within 8 weeks prior to Day 1~* Treatment with 5-fluorouracil (5-FU), imiquimod, diclofenac sodium, or photodynamic therapy: within 2 cm of the selected treatment area~Prohibited Therapies and/or Medications within 6 months prior to Day 1~* Use of systemic retinoids or biologic/monoclonal antibody therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ingenol mebutate gel, 0.015% (Type: ACTIVE_COMPARATOR): Topical field treatment once daily for 3 consecutive days on the face or scalp
- Vehicle gel (Type: PLACEBO_COMPARATOR): Topical field treatment once daily for 3 consecutive days on the face or scalp

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete